Match!
Fernando Gomez-Peralta
31Publications
7H-index
142Citations
Publications 31
Newest
#1Carlos MorillasH-Index: 13
#2Javier Escalada (University of Navarra)H-Index: 6
Last.Antonio PérezH-Index: 22
view all 0 authors...
Introduction The aim of this Delphi study is to unveil the management of patients with type 2 diabetes (T2D) and different levels of complexity in the clinical practice in Spain.
#2Itziar OyagüezH-Index: 8
Last.Miguel Ángel CasadoH-Index: 14
view all 8 authors...
FreeStyle Libre system is a sensor-based flash monitoring (FM) system, which assesses interstitial fluid glucose. The study aimed to estimate the cost associated with FM compared to self-monitoring of blood glucose (SMBG) in a type 1 diabetes mellitus (T1DM) adult population from the Spanish National Health System perspective The annual cost was modeled for glucose monitoring in T1DM with multiple daily insulin (MDI) doses in a vulnerable subgroup, such as disabled patients (blind, Down’s syndro...
#1Ana Chico (Autonomous University of Barcelona)H-Index: 12
view all 17 authors...
The flash glucose monitoring (FGM) system FreeStyle Libre® is a device that measures interstitial glucose in a very simple way and indicates direction and speed of glucose change. This allows persons with diabetes to prevent hypoglycemic and hyperglycemic events. Scientific evidence indicates that the system can improve glycemic control and quality of life. To obtain the maximum benefit, it is necessary to properly handle glucose values and trends. Due to the generalization of the system use, th...
#1Irene Romera (Eli Lilly and Company)H-Index: 10
Last.Jesús Reviriego (Eli Lilly and Company)H-Index: 9
view all 5 authors...
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are well established as effective treatments for patients with type 2 diabetes. GLP-1 RAs augment insulin secretion and suppress glucagon release via the stimulation of GLP-1 receptors. Although all GLP-1 RAs share the same underlying mechanism of action, they differ in terms of formulations, administration, injection devices and dosages. With six GLP-1 RAs currently available in Europe (namely, immediate-release exenatide, lixisenatide, lira...
Background Obesity is known to be related to the development of type 2 diabetes mellitus (T2D). The most commonly used anthropometric indicator (body mass index [BMI]) presents several limitations such as the lack of possibility to distinguish adipose tissue distribution. Thus, this study examines the suitability of a body shape index (ABSI) for prediction of body composition and sarcopenic obesity in obese or overweight T2D subjects.
Resumen La diabetes mellitus tipo 2 (DM2) es un problema de dimensiones globales por su alta y creciente prevalencia en todo el mundo y por los costes personales y economicos asociados a ella. Un tratamiento adecuado ha demostrado reducir la mortalidad y las complicaciones asociadas. Recientemente se han incluido nuevos conceptos en la practica clinica habitual y en el arbol de decision de la terapia farmacologica de la DM2. Por ello, la Sociedad Espanola de Diabetes (SED) encargo al Grupo de Tr...
#2Francisco Javier Escalada San Martín (University of Navarra)H-Index: 1
view all 12 authors...
Abstract Type 2 diabetes mellitus (DM2) has become a problem of global dimensions by their high and growing prevalence worldwide and the personal and economic costs associated with it. Correct treatment can reduce mortality and associated complications. New concepts have recently been included in routine clinical practice and have changed the algorithm of DM2 pharmacological therapy. Therefore, the Spanish Society of Diabetes (SED) entrusted to the Working Group of Consensus and Clinical Guideli...
#2Cristina AbreuH-Index: 4
Last.Guillermo E. Umpierrez (Emory University)H-Index: 59
view all 5 authors...
The safety and efficacy of dipeptidyl peptidase-4 (DPP4) inhibitors as monotherapy or in combination with other oral antidiabetic agents or basal insulin are well established. DPP4 inhibitors stimulate glucose-dependent insulin secretion and inhibit glucagon production. As monotherapy, they reduce the hemoglobin A1c level by about 0.6–0.8%. The addition of a DPP4 inhibitor to basal insulin is an attractive option, because they lower both postprandial and fasting plasma glucose concentrations wit...
1234